This study provides an innovative design strategy for developing universal 'off-the-shelf' NK cell therapies, offering significant insights into addressing immune escape and T cell exhaustion in solid tumor microenvironments, and advancing clinical optimization of PD-L1 and HLA-E dual-targeting interventions.
Literature Overview
The article titled 'Multifunctional-engineered NK cells overcome tumor immunosuppression by combining PD-L1 and HLA-E targeting and endogenous IL15 production,' published in Signal Transduction and Targeted Therapy, systematically investigates how genetically engineered NK cells can overcome tumor immunosuppressive microenvironments. The research team conducted a pan-cancer analysis revealing that PD-L1 and HLA-E are co-overexpressed across multiple tumor types and correlate with immune infiltration, suggesting their potential role as core mechanisms of immune escape. By constructing a tricistronic lentiviral vector, the study achieved simultaneous blockade of the PD-L1 and HLA-E inhibitory axes, combined with endogenous IL15 secretion, significantly enhancing NK cell survival, metabolic fitness, and anti-tumor activity. This strategy not only circumvents the toxicities commonly associated with CAR-T therapies but also provides a scalable pathway for developing 'off-the-shelf' cell therapeutics.Background Knowledge
Although tumor immunotherapy has achieved breakthroughs, its efficacy remains limited in high-risk or treatment-resistant cancers due to immunosuppressive tumor microenvironments (TME). The TME suppresses T and NK cell functions through checkpoint pathways such as PD-L1/PD-1 and HLA-E/NKG2A, leading to T cell and NK cell exhaustion. Additionally, NK cells face challenges including poor in vivo expansion, short persistence, and susceptibility to TME-mediated suppression, which restrict their clinical utility. While monoclonal antibody therapies such as anti–PD-L1 or anti–NKG2A show efficacy, their response rates are limited and require repeated administration. Therefore, developing engineered NK cells capable of autonomous response, prolonged survival, and overcoming multiple inhibitory signals represents a critical breakthrough. This study leverages the co-expression patterns of PD-L1 and HLA-E to design multifunctional NK cells that simultaneously target both pathways and self-supply IL-15, addressing three major bottlenecks of conventional NK cell therapy: immune evasion, functional suppression, and insufficient persistence.
Research Methods and Experiments
The study employed a γ-retroviral system to construct a tricistronic vector encoding the exPD1-NKG2D-4-1BB fusion receptor, soluble NKG2A-scFv, and IL15. This vector was efficiently expressed in mature NK cells derived from healthy donors, enabling stable genetic modification. An in vitro expansion system supplemented with IL-1β, IL-15, and IL-2 supported high-yield cell production. Functional validation was performed using multiple tumor cell lines (e.g., NALM-18, SK-N-AS) and patient-derived pancreatic cancer organoids (PDOs) to assess cytotoxic activity. In vivo experiments utilized immunodeficient NSG mouse models engrafted with leukemia or neuroblastoma cells to monitor NK cell distribution and tumor control. Furthermore, mass cytometry, metabolic profiling, and transcriptomic analyses were used to comprehensively characterize the phenotypic and functional remodeling of engineered NK cells.Key Conclusions and Perspectives
Research Significance and Prospects
This study presents a next-generation engineered NK platform that integrates targeting, activation, and survival functions in a 'triple-combination' design, potentially overcoming the limitations of current CAR-T or monoclonal antibody therapies in solid tumors. Particularly for tumors with heterogeneous PD-L1 expression, the exPD1-mediated signal conversion can induce antigen spreading and prevent immune escape. Moreover, the self-sustaining IL-15 strategy reduces dependence on exogenous cytokines, lowering systemic toxicity risks and making it more suitable for long-term in vivo applications.
From a drug development perspective, this platform can serve as a universal backbone, allowing further integration of additional scFv or cytokine modules for multi-target synergy. Its 'off-the-shelf' nature also supports large-scale manufacturing and stockpiling, aligning well with clinical translation needs. Future studies should evaluate safety and efficacy in patients with hematologic and solid tumors, particularly in refractory cases with low PD-L1 or high NKG2A expression, to validate its clinical advantages.
Conclusion
This study successfully engineered NK cells with potent anti-tumor activity by integrating three key functions: PD-L1 signal redirection, HLA-E/NKG2A axis blockade, and IL-15 autocrine support. The strategy effectively addresses the core challenges of NK cell survival and functional suppression within immunosuppressive microenvironments, offering a robust platform for developing universal 'off-the-shelf' cell therapies. From bench to bedside, this technology has the potential to significantly improve treatment responses in high-risk cancers, particularly in patients who do not respond to conventional immune checkpoint inhibitors. Its dual-targeting mechanism effectively prevents immune escape through single-target loss, while endogenous IL-15 support extends in vivo persistence, reduces dosing frequency, and lowers toxicity risks. In the future, by integrating patient-specific tumor microenvironment analyses, this platform could be personalized with tailored scFv or cytokine combinations, advancing precision cell therapy into a new era. For refractory solid tumors such as neuroblastoma and pancreatic cancer, this technology may become a transformative tool, offering new hope to millions of patients worldwide.
